279 related articles for article (PubMed ID: 34023215)
21. Outcomes of patients with cervical cancer treated with low- or high-dose rate brachytherapy after concurrent chemoradiation.
Scott AA; Yarney J; Vanderpuye V; Akoto Aidoo C; Agyeman M; Boateng SN; Sasu E; Anarfi K; Obeng-Mensah T
Int J Gynecol Cancer; 2021 May; 31(5):670-678. PubMed ID: 33558421
[TBL] [Abstract][Full Text] [Related]
22. Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002).
Gultekin M; Beduk Esen CS; Balci B; Alanyali S; Akkus Yildirim B; Guler OC; Yuce Sari S; Ergen SA; Sahinler I; Alsan Cetin I; Onal C; Yildiz F; Ozsaran Z
Int J Gynecol Cancer; 2021 Feb; 31(2):185-193. PubMed ID: 32998860
[TBL] [Abstract][Full Text] [Related]
23. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.
Chen SW; Liang JA; Yang SN; Ko HL; Lin FJ
Radiother Oncol; 2003 Apr; 67(1):69-76. PubMed ID: 12758242
[TBL] [Abstract][Full Text] [Related]
24. Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
Ka K; Laville A; Rassy E; Ayachi RE; Pautier P; Ba MB; Bockel S; Achkar S; Espenel S; Maulard A; Morice P; Gouy S; Haie-Meder C; Sun R; Chargari C
Gynecol Oncol; 2023 Jan; 168():32-38. PubMed ID: 36370612
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
[TBL] [Abstract][Full Text] [Related]
26. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of single insertion accelerated MR-image guided brachytherapy following chemo-radiation in locally advanced cervix cancer: modifying our EMBRACE during the COVID pandemic.
Stevens MJ; Ko F; Martland J; Brown R; Bell L; Atyeo J; Yim J
Radiat Oncol; 2023 Mar; 18(1):54. PubMed ID: 36941643
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.
Lee HJ; Kim YS; Shin SS; Nam JH; Kim YT; Han S; Choi EK
Tumori; 2012; 98(5):615-21. PubMed ID: 23235757
[TBL] [Abstract][Full Text] [Related]
29. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes.
Tinkle CL; Weinberg V; Chen LM; Littell R; Cunha JAM; Sethi RA; Chan JK; Hsu IC
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1093-1100. PubMed ID: 26194683
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
[TBL] [Abstract][Full Text] [Related]
31. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
32. Impact of different treatment plans on EQD
Gul OV; Inan G; Basaran H
J Egypt Natl Canc Inst; 2021 Oct; 33(1):28. PubMed ID: 34604928
[TBL] [Abstract][Full Text] [Related]
33. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
[TBL] [Abstract][Full Text] [Related]
34. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy.
Sood BM; Gorla G; Gupta S; Garg M; Deore S; Runowicz CD; Fields AL; Goldberg GL; Anderson PS; Vikram B
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):702-6. PubMed ID: 12062615
[TBL] [Abstract][Full Text] [Related]
35. Large volume was associated with increased risk of acute non-hematologic adverse events in the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer: preliminary results of prospective phase I/II clinical trial.
Murakami N; Watanabe M; Uno T; Sekii S; Tsujino K; Kasamatsu T; Machitori Y; Aoshika T; Kato S; Hirowatari H; Kaneyasu Y; Nakagawa T; Ikushima H; Ando K; Murata M; Yoshida K; Yoshioka H; Murata K; Ohno T; Okonogi N; Saito A; Ichikawa M; Okuda T; Tsuchida K; Sakurai H; Yoshimura R; Yoshioka Y; Yorozu A; Okamoto H; Inaba K; Kato T; Igaki H; Itami J
Jpn J Clin Oncol; 2022 Aug; 52(8):859-868. PubMed ID: 35470390
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of adjuvant vaginal vault brachytherapy in early stage cervical cancer patients.
Bronsart E; Petit C; Gouy S; Bockel S; Espenel S; Kumar T; Fumagalli I; Maulard A; Ayachy RE; Genestie C; Leary A; Pautier P; Morice P; Haie-Meder C; Chargari C
Cancer Radiother; 2020 Dec; 24(8):860-865. PubMed ID: 33129715
[TBL] [Abstract][Full Text] [Related]
37. Evolution in the management of locally advanced cervical cancer: the experience of Cancer Institute (WIA), Chennai, India.
Shanta V; Selvaluxmy G; Swaminathan R; Shanthi P
Asian Pac J Cancer Prev; 2010; 11(4):1091-8. PubMed ID: 21133630
[TBL] [Abstract][Full Text] [Related]
38. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
[TBL] [Abstract][Full Text] [Related]
39. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
40. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
